This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


Drugmaker GSK sees profit soar on consumer health spinoff

British pharmaceutical giant GlaxoSmithKline on Wednesday announced soaring annual profits thanks to the demerger of its consumer healthcare unit Haleon.

Net profit surged to £14.9 billion ($18.3 billion) last year from £4.4 billion in 2021, GSK said in a statement.

GSK posted a gain of £10.1 billion thanks to the demerger of Haleon, which became London's biggest listing for more than a decade when it was spun off last year.

The company profited last year also from strong sales of its drugs, notably its shingles vaccine Shingrix.

Total annual group revenue jumped 19 percent to £29.3 billion.

"2022 was a landmark year for GSK delivering the step change in performance we committed to, driven by strong growth in speciality medicines and vaccines, including record sales for Shingrix," GSK chief executive Emma Walmsley said in the earnings statement.

"We enter 2023 with good momentum."

Following the update, GSK's rose 0.4 percent to £14.28 on London's top tier FTSE 100 , which was up 0.1 percent overall in early trading.

"Today's full year results would appear to suggest that the business is heading in the right direction with fourth-quarter profits beating expectations," noted Michael Hewson, chief market analyst at CMC Markets UK.

© 2023 AFP

Citation: Drugmaker GSK sees profit soar on consumer health spinoff (2023, February 1) retrieved 21 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New consumer healthcare giant Haleon worth £31 bn


Feedback to editors